Clinical Trials, Phase II as Topic
"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
MeSH Number(s)
E05.318.760.535.210
E05.337.250.210
N05.715.360.775.235.210
N06.850.520.450.535.210
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in Harvard Catalyst Profiles by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 2 | 2 | 4 |
1996 | 1 | 0 | 1 |
1997 | 0 | 1 | 1 |
1998 | 1 | 2 | 3 |
1999 | 2 | 2 | 4 |
2000 | 0 | 7 | 7 |
2001 | 1 | 6 | 7 |
2002 | 1 | 6 | 7 |
2003 | 0 | 7 | 7 |
2004 | 1 | 10 | 11 |
2005 | 1 | 9 | 10 |
2006 | 3 | 11 | 14 |
2007 | 2 | 14 | 16 |
2008 | 5 | 13 | 18 |
2009 | 5 | 9 | 14 |
2010 | 5 | 9 | 14 |
2011 | 1 | 9 | 10 |
2012 | 4 | 11 | 15 |
2013 | 7 | 19 | 26 |
2014 | 8 | 18 | 26 |
2015 | 1 | 19 | 20 |
2016 | 3 | 8 | 11 |
2017 | 2 | 15 | 17 |
2018 | 2 | 21 | 23 |
2019 | 1 | 19 | 20 |
2020 | 2 | 20 | 22 |
2021 | 1 | 23 | 24 |
2022 | 1 | 17 | 18 |
2023 | 0 | 11 | 11 |
2024 | 0 | 4 | 4 |
Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.
-
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group. Neuro Oncol. 2024 03 04; 26(3):407-416.
-
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. Cancer Med. 2024 Mar; 13(5).
-
Rudi Kundini, Pamoja Kundini (RKPK): study protocol for a hybrid type 1 randomized effectiveness-implementation trial using data science and economic incentive strategies to strengthen the continuity of care among people living with HIV in Tanzania. Trials. 2024 Feb 10; 25(1):114.
-
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica. 2024 Jan 01; 109(1):343-350.
-
Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ Open. 2023 11 29; 13(11):e077427.
-
Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023 12 01; 77(6):760-768.
-
GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol. Colorectal Dis. 2023 10; 25(10):2078-2086.
-
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023 09 07; 142(10):878-886.
-
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial. BMJ Open. 2023 08 28; 13(8):e076843.
-
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19. Nat Commun. 2023 08 23; 14(1):5125.